Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services, has agreed to acquire the DNA and RNA business of Officinae Bio. This acquisition aims to bolster Maravai and its subsidiary, TriLink BioTechnologies, in supporting customers with cutting-edge nucleic acid-based therapies.

Officinae Bio, a Venice, Italy-based private technology company, specializes in a proprietary digital platform that facilitates the biological design of therapeutics. Its advanced technology allows for quick prototyping of mRNA candidates, enabling diverse tests with CAP analogs, chemical modifications, and sequence variations for clients’ discovery programs. Officinae Bio’s technology portfolio is expected to enhance Maravai’s nucleic acid production services and deliver meaningful benefits to customers developing new therapies for patients.

“Officinae Bio’s unique approach to sequence design brings a cutting-edge advantage to our Nucleic Acid Production business,” said Trey Martin, CEO of Maravai LifeSciences. “Its founder-led, experienced team maintains a dedicated focus on leveraging AI to help scale the organization and accelerate innovation. We are excited to welcome their exceptionally talented team to Maravai to help drive process and manufacturing innovation forward together.”

Adding to the enthusiasm, Justin Barbosa, GM and Vice President of TriLink Discovery, noted, “Officinae Bio’s ability to marry leading science with AI-enabled methodologies provides a one-of-a-kind sequence design experience for customers. With this acquisition, TriLink solidifies itself as an expert in mRNA design, customization, and manufacture with a high-touch digital customer experience.”

Davide De Lucrezia, CEO and co-founder of Officinae Bio, expressed his support for the acquisition, stating, "I can think of no better team with which to unite than Maravai and TriLink, whose trusted quality and leadership supports our dedication to collaboration and continuous improvement in the life sciences. We remain committed to our current customers’ success and believe this transaction will further strengthen our ability to support their needs. This business combination will also allow us to strengthen our contribution to the GMP manufacturing of key enzymes needed for nucleic acid vaccine and therapeutic applications.”

Subject to customary closing conditions and regulatory approvals, the acquisition is expected to be finalized in early 2025.